In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time.

E. Ernst,M. Klepser,M. Pfaller

DOI: https://doi.org/10.1016/S0732-8893(98)00099-6

IF: 2.983

1998-11-01

Diagnostic Microbiology and Infectious Disease

Abstract:

What problem does this paper attempt to address?

Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis

Elisabetta Pupillo,Elisa Bianchi,Valentina Bonetto,Laura Pasetto,Caterina Bendotti,Sabrina Paganoni,Jessica Mandrioli,Letizia Mazzini,RNS60-ALS Study Group

DOI: https://doi.org/10.1016/j.bbi.2024.08.044

Abstract:Background: Positive effects of RNS60 on respiratory and bulbar function were observed in a phase 2 randomized, placebo-controlled trial in people with amyotrophic lateral sclerosis (ALS). Objective: to investigate the long-term survival of trial participants and its association with respiratory status and biomarkers of neurodegeneration and inflammation. Study design and settings: A randomized, double blind, phase 2 clinical trial was conducted. Trial participants were enrolled at 22 Italian Expert ALS Centres from May 2017 to January 2020. Vital status of all participants was ascertained thirty-three months after the trial's last patient last visit (LPLV). Participants were patients with Amyotrophic Lateral Sclerosis, classified as slow or fast progressors based on forced vital capacity (FVC) slope during trial treatment. Demographic, clinical, and biomarker levels and their association with survival were also evaluated. Results: Mean duration of follow-up was 2.8 years. Long-term median survival was six months longer in the RNS60 group (p = 0.0519). Baseline FVC, and rates of FVC decline during the first 4 weeks of trial participation, were balanced between the active and placebo treatment arms. After 6 months of randomized, placebo-controlled treatment, FVC decline was significantly slower in the RNS60 group compared to the placebo group. Rates of FVC progression during the treatment were strongly associated with long-term survival (median survival: 3.7 years in slow FVC progressors; 1.6 years in fast FVC progressors). The effect of RNS60 in prolonging long-term survival was higher in participants with low neurofilament light chain (NfL) (median survival: >4 years in low NfL - RNS60 group; 3.3 years in low NfL - placebo group; 1.9 years in high NfL - RNS60 group; 1.8 years in high NfL - placebo group) and Monocyte Chemoattractant Protein-1 (MCP-1) (median survival: 3.7 years in low MCP-1 - RNS60 group; 2.3 years in low MCP-1 - placebo group; 2.8 years in high MCP-1 - RNS60 group; 2.6 years in high MCP-1 - placebo group) levels at baseline. Conclusions and relevance: In this post-hoc analysis, long term survival was longer in participants randomized to RNS60 compared with those randomized to placebo and was correlated with slower FVC progression rates, suggesting that longer survival may be mediated by the drug's effect on respiratory function. In these post-hoc analyses, the beneficial effect of RNS60 on survival was most pronounced in participants with low NfL and MCP-1 levels at study entry, suggesting that this could be a subgroup to target in future studies investigating the effects of RNS60 on survival. Trial registration: Study preregistered on 13/Jan/2017 in EUDRA-CT (2016-002382-62). The study was also registered at ClinicalTrials.gov number NCT03456882.
[Ambulant treatment of thrombotic and local inflammatory processes as well as of hematoma and contusions with hirudoid ointment].

J. Heimendinger

1953-10-15

Praxis

Abstract:
Baby mortality: getting it right for mother and baby.

C. Flint

1980-08-01

Abstract:
The use of biosensor technology for the engineering of antibodies and enzymes

A. Huber,S. Demartis,D. Neri

DOI: https://doi.org/10.1002/(SICI)1099-1352(199905/06)12:3<198::AID-JMR458>3.0.CO;2-9

1999-05-01

Journal of Molecular Recognition

Abstract:Recently developed scientific instrumentation featuring surface plasmon resonance detection allows the detection of biomolecular interactions in real time and without chemical modification of the binding partners. These biosensors are proving invaluable tools in protein engineering, particularly in research aimed at the isolation and improvement of protein binders and catalysts from macromolecular repertoires containing billions of individual members. This article reviews the use of biosensor technology for the isolation and characterization of engineered antibodies and enzymes. Copyright © 1999 John Wiley & Sons, Ltd.
The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis

Bruce D. Forrest,Namita A. Goyal,Thomas R. Fleming,Paige M. Bracci,Neil R. Brett,Zaeem Khan,Michelle Robinson,Ari Azhir,Michael McGrath

DOI: https://doi.org/10.3390/biomedicines12102367

IF: 4.757

2024-10-17

Biomedicines

Abstract:Background/Objectives: The aim of this study was to estimate the effect of a 6 months' treatment course of the innate immune modulator NP001 (a pH-adjusted intravenous formulation of purified sodium chlorite), on disease progression, as measured by overall survival (OS) in patients with amyotrophic lateral sclerosis. Methods: Blinded survival data were retrospectively collected for 268 of the 273 patients who had participated in two phase 2 placebo-controlled clinical trials of NP001 (ClinicalTrials.gov: NCT01281631 and NCT02794857) and received at least one dose of either 1 mg/kg or 2 mg/kg of NP001 as chlorite based on actual body weight, or placebo. Kaplan–Meier methods were used on the intent-to-treat population to estimate survival probabilities. Results: In the overall population, the median OS was 4.8 months (2.7 years [95% CI: 2.3, 3.5] in the 2 mg/kg NP001group and 2.3 years [95% CI: 1.8, 2.9] in the placebo group). Hazard ratio (HR): 0.77 (95% CI: 0.57, 1.03), p = 0.073. Among patients aged ≤ 65 years, the median OS for the 2 mg/kg NP001 group was 10.8 months (3.3 years [95% CI: 2.4, 3.8] in the 2 mg/kg NP001 group and 2.4 years [95% CI: 1.7, 3.3] in the placebo group). HR: 0.69 (95% CI: 0.50, 0.95). No differences were observed in the 1 mg/kg NP001 group or in patients aged > 65 years. Conclusions: The findings from this study suggest that a 6 months' treatment course of NP001 resulted in a 4.8-month increase in overall survival in patients with ALS. The findings from this study indicate that targeting inflammation associated with the innate immune system may provide a pathway for new therapeutic options for the treatment of ALS.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Retrospective observational study on the use of acetyl-l-carnitine in ALS

Serena Sassi,Elisa Bianchi,Luca Diamanti,Danilo Tornabene,Elisabetta Sette,Doriana Medici,Sabrina Matà,Deborah Leccese,Martina Sperti,Ilaria Martinelli,Andrea Ghezzi,Jessica Mandrioli,Valentina Virginia Iuzzolino,Raffaele Dubbioso,Francesca Trojsi,Carla Passaniti,Giulia D’Alvano,Massimiliano Filosto,Alessandro Padovani,Letizia Mazzini,Fabiola De Marchi,Lucia Zinno,Andi Nuredini,Paolo Bongioanni,Cristina Dolciotti,Elena Canali,Giulia Toschi,Antonio Petrucci,Alessia Perna,Vittorio Riso,Maurizio Inghilleri,Laura Libonati,Chiara Cambieri,Elisabetta Pupillo

DOI: https://doi.org/10.1007/s00415-023-11844-6

2023-06-28

Journal of Neurology

Abstract:Abstract ALCAR (Acetyl-L-carnitine) is a donor of acetyl groups and increases the intracellular levels of carnitine, the primary transporter of fatty acids across the mitochondrial membranes. In vivo studies showed that ALCAR decrease oxidative stress markers and pro-inflammatory cytokines. In a previous double-blind placebo-controlled phase II trial showed positive effects on self-sufficiency (defined as a score of 3+ on the ALSFRS-R items for swallowing, cutting food and handling utensils, and walking) ALSFRS-R total score and FVC. We conducted an observational, retrospective, multicentre, case–control study to provide additional data on the effects of ALCAR in subjects with ALS in Italy. Subjects treated with ALCAR 1.5 g/day or 3 g/day were included and matched with not treated subjects by sex, age at diagnosis, site of onset, and time from diagnosis to baseline, (45 subjects per group). ALCAR 3 g/day vs not treated: 22 not treated subjects (48.9%) were still alive at 24 months after baseline, compared to 23 (51.1%) treated subjects (adj. OR 1.18, 95% CI 0.46–3.02). No statistically significant differences were detected in ALSFRS nor FVC nor self-sufficiency. ALCAR 1.5 g/day vs not treated: 22 not treated subjects (48.9%) were still alive at 24 months after baseline, compared to 32 (71.1%) treated subjects (adj. OR 0.27, 95% CI 0.10–0.71). For ALSFRS-R, a mean slope of − 1.0 was observed in treated subjects compared to − 1.4 in those not treated ( p = 0.0575). No statistically significant difference was detected in the FVC nor self-sufficiency. Additional evidence should be provided to confirm the efficacy of the drug and provide a rationale for the dosage.

clinical neurology
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Steve Vucic,Matthew C Kiernan,Parvathi Menon,William Huynh,Austin Rynders,Karen S Ho,Robert Glanzman,Michael T Hotchkin

DOI: https://doi.org/10.1136/bmjopen-2020-041479

IF: 3.006

2021-01-01

BMJ Open

Abstract:Introduction Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluzole and edaravone have been approved by the Food and Drug Administration (FDA) . Neither riluzole nor edaravone treatment has resulted in substantial disease-modifying effects. There is, therefore, an urgent need for drugs that result in safe and effective treatment. Here, we present the design and rationale for the phase 2 RESCUE-ALS study, investigating the novel nanocatalytic drug, CNM-Au8, as a therapeutic intervention that enhances the metabolic and energetic capacity of motor neurones. CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals that have extraordinary catalytic capabilities, that enhance efficiencies of key metabolic reactions, while simultaneously reducing levels of reactive oxygen species. This trial utilises a novel design by employing motor unit number index (MUNIX), measured by electromyography, as a quantitative measure of lower motor neurone loss and as an early marker of ALS disease progression. Methods and analysis This is a multicentre, randomised, double-blind, parallel group, placebo-controlled study of the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in ALS patients. Patients will be randomised 1:1 to either receive 30 mg of CNM-Au8 once daily or matching placebo over a 36-week double-blind treatment period. Efficacy will be assessed as the change in motor neurone loss as measured by electromyography (eg, MUNIX, the primary endpoint; and secondary endpoints including MScanFit, motor unit size index, Split Hand Index, Neurophysiology Index). Exploratory endpoints include standard clinical and quality of life assessments. Ethics and dissemination RESCUE-ALS was approved by the Western Sydney Local Health District Human Research Ethics Committee (Ethics Ref: 2019/ETH12107). Results of the study will be submitted for publication in a peer-reviewed journal. Trial registration number NCT04098406

medicine, general & internal
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

Merit E. Cudkowicz,Stacy R. Lindborg,Namita A. Goyal,Robert G. Miller,Matthew J. Burford,James D. Berry,Katharine A. Nicholson,Tahseen Mozaffar,Jonathan S. Katz,Liberty J. Jenkins,Robert H. Baloh,Richard A. Lewis,Nathan P. Staff,Margaret A. Owegi,Donald A. Berry,Yael Gothelf,Yossef S. Levy,Revital Aricha,Ralph Z. Kern,Anthony J. Windebank,Robert H. Brown

DOI: https://doi.org/10.1002/mus.27472

2022-01-05

Abstract:INTRODUCTION/AIMS: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic factors (MSC-NTF), a novel autologous cell-therapy capable of targeting multiple pathways, could safely slow ALS disease progression.METHODS: This randomized, double-blind, placebo-controlled study enrolled ALS participants meeting revised El Escorial criteria, revised ALS Functional Rating Scale (ALSFRS-R) ≥25 (screening) and ≥3 ALSFRS-R points decline prior to randomization. Participants received three treatments of MSC-NTF or placebo intrathecally. The primary endpoint evaluated efficacy of MSC-NTF through a responder analysis and safety. A change in disease progression post-treatment of ≥1.25 points/mo defines a clinical response. A pre-specified analysis leveraged baseline ALSFRS-R of 35 as a subgroup threshold.RESULTS: Overall, MSC-NTF treatment was well tolerated; there were no safety concerns. Thirty-three percent of MSC-NTF and 28% of placebo participants met clinical response criteria at 28 wk (odds ratio [OR] = 1.33, P = .45); thus, the primary endpoint was not met. A pre-specified analysis of participants with baseline ALSFRS-R ≥ 35 (n = 58) showed a clinical response rate at 28 wk of 35% MSC-NTF and 16% placebo (OR = 2.6, P = .29). Significant improvements in cerebrospinal biomarkers of neuroinflammation, neurodegeneration, and neurotrophic factor support were observed with MSC-NTF, with placebo unchanged.DISCUSSION: The study did not reach statistical significance on the primary endpoint. However, a pre-specified subgroup suggests that MSC-NTF participants with less severe disease may have retained more function compared to placebo. Given the unmet patient need, the results of this trial warrant further investigation.

neurosciences,clinical neurology
Evacuation proctography: a prospective study of diagnostic and therapeutic effects.

C. Harvey,S. Halligan,C. Bartram,N. Hollings,Anjou Sahdev,K. Kingston

DOI: https://doi.org/10.1148/RADIOLOGY.211.1.R99MR16223

IF: 19.7

1999-04-01

Radiology

Abstract:PURPOSE To determine the diagnostic and therapeutic effects of evacuation proctography. MATERIALS AND METHODS Forty-seven referring clinicians completed preevacuation proctography questionnaires for 50 patients, detailing diagnoses, confidence in these, intended management, and what they hoped to learn. After evacuation proctography, the radiology report was returned with a second questionnaire asking the diagnosis in the light of evacuation proctographic findings, their confidence, and what they had learned. Clinicians quantified management contribution and indicated how useful they found evacuation proctography in general. Results from pre- and post-evacuation proctography questionnaires were compared to determine the diagnostic and therapeutic effects. RESULTS Diagnostic confidence rose significantly after evacuation proctography (mean, 7.0 before evacuation proctography vs 8.4 after evacuation proctography; P < .001). Lead diagnosis changed in nine (18%) patients. Intended surgical management became nonsurgical after evacuation proctography in seven (14%) patients, and intended nonsurgical therapy became surgical in two (4%). Surgery remained likely in 15 patients, but its nature changed in five (10%). Five (10%) clinicians stated that evacuation proctographic findings resolved diagnostic conflict, and nine (18%) found that evacuation proctographic findings revealed unsuspected diagnoses. Clinicians found evacuation proctography of major benefit in 20 (40%) cases studied and of moderate benefit in 20 (40%). In general, 20 (43%) clinicians found evacuation proctography very useful and 24 (51%) found it moderately useful. CONCLUSION Evacuation proctography has a substantial diagnostic and therapeutic effect and is of considerable benefit to referring clinicians.
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial

Jeffrey M Statland,Dan Moore,Yunxia Wang,Maureen Walsh,Tahseen Mozaffar,Lauren Elman,Sharon P Nations,Hiroshi Mitsumoto,J Americo Fernandes,David Saperstein,Ghazala Hayat,Laura Herbelin,Chafic Karam,Jonathan Katz,Heather M Wilkins,Abdulbaki Agbas,Russell H Swerdlow,Regina M Santella,Mazen M Dimachkie,Richard J Barohn,Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium,Russell Swerdlow,Jeffrey Statland,Melanie Glenn,Mamatha Pasnoor,Kelley Emmons,Kathryn Johns,Yolanda Harness,Robert G Miller,Dallas Forshew,Marguerite Engel,Namita Goyal,Tiyonnoh Cash,Veena Mathew,Veronica Martin,Todd Levine,Lynn Flynne,Diana Dimtrov,Leo McCluskey,Kelly Almasy,Mary Kelley,J Americo M Fernandes,Pariwat Thaisetthawatkul,Carolyn Peterson,Cindy Cowardin,Peggy Heires,Sharon Nations,Jaya Trivedi,Nina F Gorham,Steve Hopkins,Susan Brown,Sonya Aziz-Zaman,Jonathan Hupf,Nicole Armstrong,Brittany McHale,Heather Wilkins,Jessica Sage,Sharice Hall,Regina Santella,Irina Gurvich,Anthony Amato,Richard Bedlack,Carlayne Jackson,Gary Cutter,Gil Wolfe,Ericka Simpson

DOI: https://doi.org/10.1002/mus.26335

Abstract:Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve 59:201-207, 2019.
A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial

Venkataramanan Srinivasan,Victoria Homer,Darren Barton,Abigail Clutterbuck-James,Siân Jenkins,Claire Potter,Kristian Brock,Ann Logan,Donna Smith,Lars Bruce,Zsuzsanna Nagy,Simon P Bach

DOI: https://doi.org/10.1371/journal.pone.0291285

IF: 3.7

2024-07-11

PLoS ONE

Abstract:Background: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig´s disease, is a rare neurological condition and is the most common motor neurone disease. It is a fatal disease with specific loss of motor neurons in the spinal cord, brain stem, and motor cortex leading to progressive paralysis and usually death within five years of diagnosis. There remains no cure for ALS, and management is focused on a combination of neuroprotective medication, respiratory support, and management by multidisciplinary clinics. Patients and methods: This prospective, single-arm, open-label phase II clinical trial of sustained weekly administration of 2 mg/kg ILB® (a low-molecular weight dextran sulphate) was conducted in a single UK hospital. Eligible patients were at least 18 years and had a definite diagnosis of ALS according to El Escorial Criteria. The co-primary outcomes were safety, tolerability, and quantity of ILB® administered. EudraCT number. 2018-000668-28. Findings: Between 18-Apr-2019 and 27-Mar-2020, 11 patients were recruited and treated for up to 38 weeks. There were no treatment terminations or withdrawals. One serious adverse event was reported, which was not related to ILB® and resolved without sequalae. 270 mild/moderate adverse events were reported with no intolerable events occurring during the trial. The total number of ILB® treatments administered per patient ranged from 4 to 38, with a cumulative dose ranging from 745 to 6668 mg. As a result of the COVID-19 pandemic and the high-risk status of study participants, recruitment and treatment was suspended early in Mar-2020. At the long-term follow-up, three patients had died after the trial was halted, between 53 and 62 weeks after their final ILB® injection. Interpretation: Long-term weekly ILB® injections of 2 mg/kg was well tolerated and had an acceptable safety profile in patients with ALS. Trial registration: EudraCT: 2018-000668-28. clinicaltrials.gov: NCT03705390. This trial adheres to the principles of GCP in the design, conduct, recording and reporting of clinical trials as listed in part 2, "Conditions and Principles which apply to all Clinical Trials" under the header "Principles based on Articles 2 to 5 of the EU GCP Directive" in the Medicines for Human Use Clinical Trials Regulations (as amended in SI 2006/1928). For clarity, the study did not conform to all aspects of the International Conference on Harmonisation (ICH) E6 R2 Guidelines for GCP (also known as 'ICH GCP'). Of note, we did not use an external database, perform 100% source data verification, and only primary outcome data were analysed in parallel by a second, independent statistician.
Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

Vincent Meininger,Pierre-François Pradat,Andrea Corse,Safa Al-Sarraj,Benjamin Rix Brooks,James B. Caress,Merit Cudkowicz,Stephen J. Kolb,Dale Lange,P. Nigel Leigh,Thomas Meyer,Stefano Milleri,Karen E. Morrison,Richard W. Orrell,Gary Peters,Jeffrey D. Rothstein,Jeremy Shefner,Arseniy Lavrov,Nicola Williams,Phil Overend,Jeffrey Price,Stewart Bates,Jonathan Bullman,David Krull,Alienor Berges,Bams Abila,Guy Meno-Tetang,Jens Wurthner

DOI: https://doi.org/10.1371/journal.pone.0097803

IF: 3.7

2014-05-19

PLoS ONE

Abstract:The neurite outgrowth inhibitor, Nogo-A, has been shown to be overexpressed in skeletal muscle in amyotrophic lateral sclerosis (ALS); it is both a potential biomarker and therapeutic target. We performed a double-blind, two-part, dose-escalation study, in subjects with ALS, assessing safety, pharmacokinetics (PK) and functional effects of ozanezumab, a humanized monoclonal antibody against Nogo-A. In Part 1, 40 subjects were randomized (3∶1) to receive single dose intravenous ozanezumab (0.01, 0.1, 1, 5, or 15 mg/kg) or placebo. In Part 2, 36 subjects were randomized (3∶1) to receive two repeat doses of intravenous ozanezumab (0.5, 2.5, or 15 mg/kg) or placebo, approximately 4 weeks apart. The primary endpoints were safety and tolerability (adverse events [AEs], vital signs, electrocardiogram (ECG), and clinical laboratory tests). Secondary endpoints included PK, immunogenicity, functional endpoints (clinical and electrophysiological), and biomarker parameters. Overall, ozanezumab treatment (0.01-15 mg/kg) was well tolerated. The overall incidence of AEs in the repeat dose 2.5 mg/kg and 15 mg/kg ozanezumab groups was higher than in the repeat dose placebo group and repeat dose 0.5 mg/kg ozanezumab group. The majority were considered not related to study drug by the investigators. Six serious AEs were reported in three subjects receiving ozanezumab; none were considered related to study drug. No study drug-related patterns were identified for ECG, laboratory, or vital signs parameters. One subject (repeat dose 15 mg/kg ozanezumab) showed a weak, positive anti-ozanezumab-antibody result. PK results were generally consistent with monoclonal antibody treatments. No apparent treatment effects were observed for functional endpoints or muscle biomarkers. Immunohistochemical staining showed dose-dependent co-localization of ozanezumab with Nogo-A in skeletal muscle. In conclusion, single and repeat dose ozanezumab treatment was well tolerated and demonstrated co-localization at the site of action. These findings support future studies with ozanezumab in ALS.TRIAL REGISTRATION: ClinicalTrials.gov NCT00875446 GSK-ClinicalStudyRegister.com GSK ID 111330.

multidisciplinary sciences
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

Merit Cudkowicz,Michael E Bozik,Evan W Ingersoll,Robert Miller,Hiroshi Mitsumoto,Jeremy Shefner,Dan H Moore,David Schoenfeld,James L Mather,Donald Archibald,Mary Sullivan,Craig Amburgey,Juliet Moritz,Valentin K Gribkoff

DOI: https://doi.org/10.1038/nm.2579

2011-11-20

Abstract:Amyotrophic lateral sclerosis (ALS) is characterized by upper and lower motor neuron dysfunction and loss, rapidly progressive muscle weakness, wasting and death. Many factors, including mitochondrial dysfunction, may contribute to ALS pathogenesis. Riluzole, which has shown only modest benefits in a measure of survival time without demonstrated effects on muscle strength or function, is the only approved treatment for ALS. We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In part 1, the effects of dexpramipexole (50, 150 or 300 mg d(-1)) versus placebo were assessed over 12 weeks. In part 2, after a 4-week, single-blind placebo washout, continuing subjects were re-randomized to dexpramipexole at 50 mg d(-1) or 300 mg d(-1) as double-blind active treatment for 24 weeks. Dexpramipexole was safe and well tolerated. Trends showing a dose-dependent attenuation of the slope of decline of the ALS Functional Rating Scale-Revised (ALSFRS-R) in part 1 and a statistically significant (P = 0.046) difference between groups in a joint rank test of change from baseline in ALSFRS-R and mortality in part 2 strongly support further testing of dexpramipexole in ALS.
In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis

Joachim Schuster,Jens Dreyhaupt,Karla Mönkemöller,Luc Dupuis,Stéphane Dieterlé,Jochen H. Weishaupt,Jan Kassubek,Susanne Petri,Thomas Meyer,Julian Grosskreutz,Berthold Schrank,Matthias Boentert,Alexander Emmer,Andreas Hermann,Daniel Zeller,Johannes Prudlo,Andrea S. Winkler,Torsten Grehl,Michael T. Heneka,Siw Johannesen,Bettina Göricke,Simon Witzel,Johannes Dorst,Albert C. Ludolph,the RAS‐ALS Study Group

DOI: https://doi.org/10.1111/ene.16204

2024-01-21

European Journal of Neurology

Abstract:Background and purpose In 2016, we concluded a randomized controlled trial testing 1 mg rasagiline per day add‐on to standard therapy in 252 amyotrophic lateral sclerosis (ALS) patients. This article aims at better characterizing ALS patients who could possibly benefit from rasagiline by reporting new subgroup analysis and genetic data. Methods We performed further exploratory in‐depth analyses of the study population and investigated the relevance of single nucleotide polymorphisms (SNPs) related to the dopaminergic system. Results Placebo‐treated patients with very slow disease progression (loss of Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised [ALSFRS‐R] per month before randomization of ≤0.328 points) showed a per se survival probability after 24 months of 0.85 (95% confidence interval = 0.65–0.94). The large group of intermediate to fast progressing ALS patients showed a prolonged survival in the rasagiline group compared to placebo after 6 and 12 months (p = 0.02, p = 0.04), and a reduced decline of ALSFRS‐R after 18 months (p = 0.049). SNP genotypes in the MAOB gene and DRD2 gene did not show clear associations with rasagiline treatment effects. Conclusions These results underline the need to consider individual disease progression at baseline in future ALS studies. Very slow disease progressors compromise the statistical power of studies with treatment durations of 12–18 months using clinical endpoints. Analysis of MAOB and DRD2 SNPs revealed no clear relationship to any outcome parameter. More insights are expected from future studies elucidating whether patients with DRD2CC genotype (Rs2283265) show a pronounced benefit from treatment with rasagiline, pointing to the opportunities precision medicine could open up for ALS patients in the future.

neurosciences,clinical neurology
Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study

Olga Paoletti,Giulia Hyeraci,Marco Finochietti,Maria Grazia Celani,Ilaria Bacigalupo,Niccolò Lombardi,Giada Crescioli,Marco Tuccori,Silvia Cascini,Rosa Gini,Antonio Addis,Ursula Kirchmayer,CAESAR study group

DOI: https://doi.org/10.1111/ene.16470

2024-09-21

European Journal of Neurology

Abstract:Background and purpose The purpose was to describe the use patterns of pharmacological and non‐pharmacological therapies and investigate potential determinants of riluzole use in patients newly diagnosed with amyotrophic lateral sclerosis (ALS) in three Italian regions. Methods Amyotrophic lateral sclerosis patients were selected from administrative healthcare databases of Latium, Tuscany and Umbria from 1 January 2014 to 31 December 2019 based on hospital‐ and disease‐specific co‐payment exemption data. The first trace of ALS was considered the index date. Incident ALS cases were those without a trace of ALS during the 3‐year look back. Patients were described in terms of demographics, clinical characteristics and drug use at baseline, and were classified into four categories based on riluzole use in the 2 years before and 1 year after the index date: prevalent, incident, former users and non‐users. Use of symptomatic pharmacological and non‐pharmacological therapies was described across these categories during 12 months after the index date. Determinants of riluzole use were also investigated. Results and conclusions A total of 1636 ALS incident subjects were detected in the three regions, mainly aged 65–74 years. Patients were generally fragile with a high prevalence of comorbidities at baseline. Riluzole was used by 27.4% of the overall study cohort at baseline and steeply increased in the first year after the index date differently between regions (Latium 61.2%, Tuscany 85.0%, Umbria 76.5%), with about half of the subjects being incident users. In the 12 months after the index date, also symptomatic therapies increased, in riluzole users and non‐users. Determinants analysis showed that higher patient severity and complexity were associated with a lower likelihood of being treated with riluzole.

neurosciences,clinical neurology
Challenges and promises in optimising a non-clinical protocol of intracerebroventricular human neural stem cell transplantation in ALS

Ivan Lombardi,Clelia Ferrero,Edvige Vulcano,Daniela Maria Rasa',Maurizio Gelati,Diego Pastor Campos,Rose Mary Carletti,Silvia De La Morena,Daniela Celeste Profico,Sabrina Longobardi,Elisa Lazzarino,Elisa Perciballi,Jessica Rosati,Salvador Martinez Perez,Alessandro Vercelli,Marina M. Boido,Daniela Ferrari

DOI: https://doi.org/10.1101/2024.11.18.624143

2024-11-19

Abstract:Background and aims: Neural stem cell (NSC) transplantation holds promising therapeutic potential for neurodegenerative disorders like amyotrophic lateral sclerosis (ALS). However, pre-clinical studies and early-phase clinical trials have faced challenges hindering the effective clinical translation of this approach. Crucial hurdles include the side-effects of prolonged immunosuppression, concerns regarding cell origin and transplantation dosage, identification of the most appropriate therapeutic window, and invasiveness of surgical procedures. Here, we show challenges and promises in optimizing a non-clinical protocol to assess safety and efficacy of human NSC (hNSC) intracerebroventricular (ICV) transplantation for ALS. Methods: We evaluated the safety of administering up to 1x106 hNSCs in immunodeficient mice and assessed their potential efficacy in reducing ALS hallmarks employing the SOD1G93A mouse model. Both, transient (15 days) and prolonged immunosuppression regimens, at low (15 mg/kg) and high (30 mg/kg) doses, were tested along with two different cell dosages (3x105 and 1x106). Results: Bilateral ICV injection of up to 1x106 hNSCs proved to be safe, with no evidence of tumor formation. At 40 days post-transplantation, hNSCs induced a trend toward delaying motor decline and reducing spinal cord (SC) microgliosis when transplanted under prolonged high-dose (30 mg/kg) immunosuppression. Conclusions: Our study suggests that: (i) a bilateral ICV transplantation of 1x106 hNSCs is safe and non-tumorigenic in immunodeficient hosts; (ii) sustained high-dose immunosuppression is essential for ensuring cell survival in immunocompetent mice; and (iii) hNSC transplantation may provide therapeutic benefits in ALS by delaying motor decline and reducing microgliosis. This study also highlights persisting hurdles that need to be further addressed, such as the aggressive murine immune response to exogenous cells.

Biology
Systemic Innate Immune System Restoration as a Therapeutic Approach for Neurodegenerative Disease: Effects of NP001 on Amyotrophic Lateral Sclerosis (ALS) Progression

Michael S. McGrath,Rongzhen Zhang,Paige M. Bracci,Ari Azhir,Bruce D. Forrest

DOI: https://doi.org/10.3390/biomedicines12102362

IF: 4.757

2024-10-17

Biomedicines

Abstract:Background/objective: Amyotrophic lateral sclerosis (ALS) is a diagnosis that incorporates a heterogeneous set of neurodegenerative processes into a single progressive and uniformly fatal disease making the development of a uniformly applicable therapeutic difficult. Recent multinational ALS natural history incidence studies have identified systemic chronic activation of the innate immune system as a major risk factor for developing ALS. Persistent immune activation in patients with ALS leads to loss of muscle and lowering of serum creatinine. The goal of the current study was to test whether the slowing of nerve and muscle destruction in NP001-treated ALS patients compared with controls in phase 2 studies would lead to extension of survival. Methods: Phase 2 clinical studies with NP001, an intravenously administered form of the innate immune system regulator NaClO2, are now reporting long-term survival benefits for drug recipients vs. placebo controls after only six months of intermittent treatment. As a prodrug, NP001 is converted by macrophages to taurine chloramine, a long-lived regulator of inflammation. We performed a pooled analysis of all patients who had completed the studies in two six-month NP001 phase 2 trials. Changes in respiratory vital capacity and the muscle mass product, creatinine, defined treated patients who, compared to placebo, had up to a year of extended survival. Conclusions: The observed longer survival in ALS patients with the greatest inflammation-associated muscle loss provides further evidence that ALS is a disease of ongoing innate immune dysfunction and that NP001 is a disease-modifying drug with sustained clinical activity.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
New metabolites, tetrahydrofuran lignans, produced by Streptomyces sp. IT-44.

Y. Chiung,H. Hayashi,H. Matsumoto,T. Otani,Kenzaburo Yoshida,Ming-Yu Huang,Ruxian Chen,Jing-Rong Liu,M. Nakayama

DOI: https://doi.org/10.7164/ANTIBIOTICS.47.487

1994-04-25

Abstract:
Radiation-induced cerebral aneurysms

D. Scodary,J. Tew,G. Thomas,T. Tomsick,B. Liwnicz

DOI: https://doi.org/10.1007/BF01405429

Acta Neurochirurgica

Abstract:
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

Alberto J Espay,Fabrizio Stocchi,Rajesh Pahwa,Alberto Albanese,Aaron Ellenbogen,Joaquim J Ferreira,Nir Giladi,Tanya Gurevich,Sharon Hassin-Baer,Jorge Hernandez-Vara,Stuart H Isaacson,Karl Kieburtz,Peter A LeWitt,Lydia Lopez-Manzanares,C Warren Olanow,Werner Poewe,Harini Sarva,Tami Yardeni,Liat Adar,Laurence Salin,Nelson Lopes,Nissim Sasson,Ryan Case,Olivier Rascol,BouNDless Study Group,Mitra Afshari,Alexander Amelin,David Arkadir,Samih Badarny,Ernest Balaguer Martinez,Andrzej Bogucki,James Boyd,Laura Buyan Dent,Camille Carroll,Kallol Ray Chaudhuri,Jeffrey Cooney,Anne-Gaëlle Corbillé,Teodor Danaila,Maria Francesca De Pandis,Sophie Dethy,Rohit Dhall,Ruth Djaldetti,Franck Durif,Stephen Flitman,Eric Freire Alvarez,John Goudreau,Francisco Grandas Perez,Tanya Gurevich,Arnaldo Isa,Jorge L Juncos,Sulada Kanchana,Gabriela Klodowska-Duda,Dariusz Koziorowski,Jaime Kulisevsky Bojarski,Juan Lopez Lozano,Lan Luo,Nataliya Lytvynenko,Roberto Marconi,Ana-Raquel Marques,Juan Carlos Martinez Castrillo,Irene Martinez Torres,Aashoo Mentreddi,Pablo Mir Rivera,Sergii Moskovko,Yuliya Neryanova,Marco Onofrj,Jill Ostrem,Claudio Pacchetti,Nicola Pavese,Clelia Pellicano,Gonzalo Revuelta,Ana Margarida Rodrigues,Ramon Rodriguez,Monika Rudzinska,Nighat Sarwar,Julie Schwartzbard,Laura Scorr,John Slevin,Tatyana Slobodin,Gianfranco Spalletta,Michele Tagliati,Yen Tai,Alessandro Tessitore,Peter Valkovic,Leo Verhagen,Elena Vostrikova,Gilad Yahalom,Zuleykha Zalyalova,Katerina Zarubova,Irina Zhukova

DOI: https://doi.org/10.1016/s1474-4422(24)00052-8

IF: 59.935

2024-03-01

The Lancet Neurology

Abstract:BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) compared with oral immediate-release levodopa-carbidopa for the treatment of motor fluctuations in people with Parkinson's disease.METHODS: We conducted a phase 3, randomised, double-blind, double-dummy, active-controlled, multicentre trial at 117 academic and community neurology sites in 16 countries, including in Europe, Israel, and the USA. Eligible participants were men and women aged 30 years or older with a diagnosis of Parkinson's disease (Hoehn and Yahr stage ≤3 in the on state) who experienced at least 2·5 h/day of off time. Participants underwent an open-label run-in phase (<12 weeks), during which time optimal regimens were established for both oral immediate-release levodopa-carbidopa and for 24 h/day subcutaneous ND0612 infusion (levodopa-carbidopa 60·0/7·5 mg/mL), with supplemental oral levodopa-carbidopa if needed. Participants were then randomly assigned (1:1) to 12 weeks of double-blind treatment with their optimised regimen of either subcutaneous ND0612 or oral levodopa-carbidopa, with matching oral or subcutaneous placebo given as required to maintain blinding. Randomisation was done via an interactive web response system, stratified by region, using a permuted block schedule. Participants, study partners, treating investigators, study site personnel, and the sponsor were masked to treatment group allocation. The primary efficacy endpoint was the change from baseline (ie, time of randomisation, when all patients were receiving an optimised open-label ND0612 regimen) to end of the double-blind phase in total daily on time without troublesome dyskinesia, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, NCT04006210, and is complete.FINDINGS: Between Sept 30, 2019, and April 8, 2022, 381 participants were enrolled, of whom 259 (68%) were randomly assigned, 128 (49%) to subcutaneous ND0612 and 131 (51%) to oral levodopa-carbidopa. 243 (94%) participants completed the study. Treatment with subcutaneous ND0612 provided an additional 1·72 h (95% CI 1·08 to 2·36) of on time without troublesome dyskinesia compared with oral levodopa-carbidopa (change from baseline of -0·48 h [-0·94 to -0·02] with subcutaneous ND0612 vs -2·20 h [-2·65 to -1·74] with oral levodopa-carbidopa; p<0·0001). Significant treatment differences favouring subcutaneous ND0612 were also found in the first four of nine prespecified hierarchical outcomes of daily off time (-1·40 h [95% CI -1·99 to -0·80]), Movement Disorders Society-Unified Parkinson's Disease Rating Scale part II scores (-3·05 [-4·28 to -1·81]), Patients Global Impression of Change (odds ratio [OR] 5·31 [2·67 to 10·58]), and Clinical Global Impression of Improvement (OR 7·23 [3·57 to 14·64]). Hierarchical testing ended after the fourth secondary endpoint. Adverse events were reported by 287 (89%) of 322 participants during open-label ND0612 optimisation, and by 103 (80%) of 128 in the ND0612 group and 97 (74%) of 131 in the oral levodopa-carbidopa group during the double-blind phase. The most common adverse events were infusion-site reactions (266 [83%] participants during open-label ND0612, and 73 [57%] in the ND0612 group vs 56 [43%] in the oral levodopa-carbidopa group during the double-blind phase), most of which were mild. Serious adverse events in four participants in the ND0612 group were related to study treatment (infusion-site cellulitis [n=2], infusion-site abscess and infusion-site ulcer [n=1]; and paraesthesia and peripheral sensorimotor neuropathy [n=1]). One participant in the ND0612 group died during the double-blind phase, but the death was not related to study treatment (fall leading to traumatic brain injury).INTERPRETATION: Results of this phase 3 study showed that subcutaneous ND0612 used in combination with oral immediate-release levodopa-carbidopa increased on time without troublesome dyskinesia and reduced off time, with a favourable benefit-risk profile. ND0612 might offer a safe and efficacious subcutaneous levodopa infusion approach to managing motor fluctuations in people with Parkinson's disease. The ongoing open-label extension phase will provide further information on the long-term efficacy and safety of treatment.FUNDING: NeuroDerm.

clinical neurology

In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time.

Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis

[Ambulant treatment of thrombotic and local inflammatory processes as well as of hematoma and contusions with hirudoid ointment].

Baby mortality: getting it right for mother and baby.

The use of biosensor technology for the engineering of antibodies and enzymes

The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis

Retrospective observational study on the use of acetyl-l-carnitine in ALS

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

Evacuation proctography: a prospective study of diagnostic and therapeutic effects.

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial

A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial

Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis

Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study

Challenges and promises in optimising a non-clinical protocol of intracerebroventricular human neural stem cell transplantation in ALS

Systemic Innate Immune System Restoration as a Therapeutic Approach for Neurodegenerative Disease: Effects of NP001 on Amyotrophic Lateral Sclerosis (ALS) Progression

New metabolites, tetrahydrofuran lignans, produced by Streptomyces sp. IT-44.

Radiation-induced cerebral aneurysms

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial